Stevanato Group reported third-quarter fiscal 2026 revenue of €326.1 million, an 8% increase from the prior year period, driven by an 11% organic growth in its Biopharmaceutical and Diagnostic Solutions segment that offset a 12% decline in Engineering revenue. Adjusted EBITDA rose 14% to €88.8 million with a margin expansion of 150 basis points to 27.2%, while diluted earnings per share grew 15% to €0.15. The company maintained its full-year guidance, expecting revenue between €1.26 billion and €1.28 billion, adjusted EBITDA of €335 million to €345.2 million, and adjusted diluted EPS of €0.60 to €0.62. Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries.
